1563P - The Use of Biosimilars in the Management of Chemotherapy-Induced Anaemia (CIA) in Solid Tumours, Lymphoma and Myeloma: the Orheo Study

Abstract

ABSTRACT The approval of epoetin biosimilars in the European Union requires extensive scientific evaluation and stringent regulatory procedures, including post-marketing studies. The ORHEO (place of biOsimilaRs in the therapeutic management of anaemia secondary to chemotherapy in HaEmatology and Oncology) study was an observational, longitudinal, multicentre study performed in France to evaluate the efficacy and safety of biosimilar epoetins for the treatment of CIA in the clinical setting. Patients >18 years with CIA (haemoglobin [Hb] 2310 patients (mean age 66.5 years) from 232 centres were included, of whom 79.6% had solid tumours, 13.0% had lymphoma and 7.4% myeloma. Of those patients with solid tumours, 30.1% of patients had a stage III and 21.6% had a stage IV tumour. Almost all patients received the biosimilar epoetin zeta (Retacrit®, Hospira UK Ltd., median dose 30,000 IU/week). Mean baseline Hb level across all patients was 9.6 g/dL, with 35.6% of patients having moderate anaemia (Hb 8–9.5 g/dL). Following treatment, Hb response was achieved in 81.6% and 86.5% of patients at 3 and 6 months, respectively. The overall mean change in Hb level was 1.5 ± 1.6 g/dL at 3 months and 1.72 ± 1.61 g/dL at 6 months. Transfusion rates were 9.4% and 5.8%, while the rate of thromboembolic events was 2.4% and 1.5%, at 3 and 6 months respectively. In conclusion, Retacrit was effective and well tolerated in the management of CIA in patients with solid tumours, lymphoma and myeloma. Disclosure M. Michallet: I received honoraria from Hospira for advisory boards and consulting, P. Soubeyran: I received honoraria from Hospira for advisory boards and consulting, H. Albrand: Employed by Hospira, E. Luporsi: I received honoraria from Hospira for advisory boards and consulting.